Imitrex Tablets are indicated for the acute treatment of migraine attacks with or without aura, but not for use in the management of basilar or hemiplegic migraine or cluster headache. Imitrex should only be used where a clear diagnosis of migraine has been established. Imitrex should not be used in patients with ischemic heart disease, symptoms or signs consistent with ischemic heart disease, or Prinzmetal's angina because of rare reports of coronary vasospasm. Imitrex should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In clinical trials for Imitrex Tablets, the most common side effects seen included tingling and nasal discomfort.
Most side effects are mild and transient.
Imitrex Tablets are available in more than 75 countries, including Canada, the United Kingdom and Mexico. Imitrex Injection is also available in more than 75 countries. Glaxo Wellcome Inc., based in Research Triangle Park, N.C., is the nation's leading research-based pharmaceutical firm. A subsidiary of London-based Glaxo Wellcome plc, the company discovers, develops, and distributes innovative medicines that improve patient health and quality of life. Please contact us with any comments, problems or bugs.